Perampanel in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Expert Review of Clinical Pharmacology

• Publication date

  2015-10-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/17512433.2015.1091303PMID 26436331
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Therapeutic Advances in Neurological Disorders

  2017cited by this paper
• Brivaracetam in Unverricht‐Lundborg disease (EPM1): Results from two randomized, double‐blind, placebo‐controlled studies

  2016cited by this paper
• Efficacy of Adjunctive Perampanel in Idiopathic Generalized Epilepsy Patients with Drug-Resistant Primary Generalized Tonic-Clonic Seizures by Age, Sex, and Race: Double-Blind Placebo-Controlled Phase III Study (P2.021)

  2016cited by this paper
• Transition from intravenous to enteral ketamine for treatment of nonconvulsive status epilepticus

  2016cited by this paper
• Brivaracetam, a selective high‐affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action

  2016cited by this paper
• Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures

  2015cited by this paper
• Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug.

  2015cited by this paper
• Anti‐ictogenic and antiepileptogenic properties of brivaracetam in mature and immature rats

  2015cited by this paper
• Effect of brivaracetam on CYP3A activity, measured by oral midazolam

  2015cited by this paper
• Brivaracetam augments short‐term depression and slows vesicle recycling

  2015cited by this paper
• Effectiveness and Tolerability of Perampanel in Children and Adolescents with Refractory Epilepsies: First Experiences

  2015influential reference
• A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures

  2015cited by this paper
• Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study.

  2015cited by this paper
• A randomized, double‐blind, placebo‐controlled, multicenter, parallel‐group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial‐onset seizures

  2015cited by this paper
• Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII).

  2015cited by this paper
• Brivaracetam and carbamazepine interaction in healthy subjects and in vitro.

  2015cited by this paper
• Efficacy and safety of perampanel in the subgroup of elderly patients included in the phase III epilepsy clinical trials.

  2015cited by this paper
• Adjunctive brivaracetam for patients with refractory partial seizures: A meta-analysis of randomized placebo-controlled trials.

  2015cited by this paper
• Perampanel efficacy and safety by gender: Subanalysis of phase III randomized clinical studies in subjects with partial seizures

  2015cited by this paper
• Costs of epilepsy and cost‐driving factors in children, adolescents, and their caregivers in Germany

  2015cited by this paper
• Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel.

  2015cited by this paper
• Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy

  2015influential reference
• Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit.

  2015cited by this paper
• An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam.

  2015cited by this paper
• Perampanel in the treatment of partial seizures: Time to onset and duration of most common adverse events from pooled Phase III and extension studies.

  2015cited by this paper
• The efficacy and safety of brivaracetam at different doses for partial-onset epilepsy: a meta-analysis of placebo-controlled studies

  2015cited by this paper
• Absence of Liver Toxicity in Perampanel-Treated Subjects: Pooled results from partial seizure phase III perampanel clinical studies.

  2015cited by this paper
• The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist

  2015cited by this paper
• Efficacy of perampanel in refractory nonconvulsive status epilepticus and simple partial status epilepticus.

  2015influential reference
• Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.

  2015cited by this paper
• Cost of status epilepticus: A systematic review.

  2015cited by this paper
• Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel

  2015cited by this paper
• First clinical experiences with perampanel—The Kork experience in 74 patients

  2014influential reference
• Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: Results from a double‐blind, randomized, placebo‐controlled trial

  2014cited by this paper
• Possible effect of perampanel on focal status epilepticus after generalized tonic–clonic status epilepticus

  2014cited by this paper
• Prevention of generalized tonic–clonic seizures in refractory focal epilepsy: A meta‐analysis

  2014cited by this paper
• Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: A phase III randomized, double‐blind, placebo‐controlled trial

  2014cited by this paper
• Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: Results of a phase III, double‐blind, randomized, placebo‐controlled, flexible‐dose trial

  2014cited by this paper
• Perampanel for adjunctive treatment of partial‐onset seizures: A pooled dose–response analysis of phase III studies

  2014cited by this paper
• Interaction between brivaracetam (100 mg/day) and a combination oral contraceptive: A randomized, double‐blind, placebo‐controlled study

  2014cited by this paper
• Adverse effects and safety profile of perampanel: A review of pooled data

  2014cited by this paper
• Clinical experience with perampanel: focus on psychiatric adverse effects.

  2014cited by this paper
• Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: Results from phase III extension study 307

  2014cited by this paper
• A multicenter survey of clinical experiences with perampanel in real life in Germany and Austria.

  2014cited by this paper
• Brivaracetam single and multiple rising oral dose study in healthy Japanese participants: influence of CYP2C19 genotype.

  2014cited by this paper
• The discovery and development of perampanel for the treatment of epilepsy

  2014cited by this paper
• Seizure control and improvement of neurological dysfunction in Lafora disease with perampanel

  2014cited by this paper
• Brivaracetam Differentially Affects Voltage‐Gated Sodium Currents Without Impairing Sustained Repetitive Firing in Neurons

  2014cited by this paper
• Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial‐onset seizures: A phase IIb, randomized, controlled trial

  2013cited by this paper
• Concentration–effect relationships with perampanel in patients with pharmacoresistant partial‐onset seizures

  2013cited by this paper
• Synaptic vesicle protein 2A: basic facts and role in synaptic function

  2013cited by this paper
• Inpatient treatment costs of status epilepticus in adults in Germany.

  2013cited by this paper
• Preclinical pharmacology of perampanel, a selective non‐competitive AMPA receptor antagonist

  2013cited by this paper
• Sustained seizure remission on perampanel in progressive myoclonic epilepsy (Lafora disease)☆

  2013cited by this paper
• Systematic Review and Meta-Analysis of the Efficacy and Safety of Perampanel in the Treatment of Partial-Onset Epilepsy

  2013cited by this paper
• The adverse event profile of perampanel: meta‐analysis of randomized controlled trials

  2013cited by this paper
• Brivaracetam Disposition in Mild to Severe Hepatic Impairment

  2013cited by this paper
• Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany.

  2013cited by this paper
• Evaluation of adjunctive perampanel in patients with refractory partial‐onset seizures: Results of randomized global phase III study 305

  2013cited by this paper
• Safety and tolerability of perampanel: a review of clinical trial data

  2013cited by this paper
• Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: A pooled analysis of three phase III studies

  2013cited by this paper
• Progressive myoclonus epilepsy.

  2013cited by this paper
• Brivaracetam Disposition in Renal Impairment

  2012cited by this paper
• Cost of Epilepsy

  2012cited by this paper
• Tritium‐Labeled Brivaracetam with High Specific Activity: Preparation, Characterization and Application in Human Brain Samples

  2012cited by this paper
• Tolerability and safety of perampanel: two randomized dose‐escalation studies

  2012cited by this paper
• The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy.

  2012influential reference
• Adjunctive perampanel for refractory partial-onset seizures

  2012cited by this paper
• Randomized phase III study 306

  2012cited by this paper
• Drug-resistant epilepsy.

  2011cited by this paper
• Basic mechanisms of antiepileptic drugs and their pharmacokinetic/pharmacodynamic interactions: an update

  2011cited by this paper
• Rational polytherapy in the treatment of acute seizures and status epilepticus

  2011cited by this paper
• The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol.

  2011influential reference
• Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.

  2011cited by this paper
• Brivaracetam (UCB 34714)

  2011cited by this paper
• Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trials.

  2011cited by this paper
• Satellite symposia

  2011cited by this paper
• Relationship of clinical and quality of life trajectories following the onset of seizures: Findings from the UK MESS Study

  2011cited by this paper
• Kynurenic acid and kynurenine aminotransferases in retinal aging and neurodegeneration

  2011cited by this paper
• Remission and relapse in a drug‐resistant epilepsy population followed prospectively

  2011cited by this paper
• Perampanel: A novel, orally active, noncompetitive AMPA‐receptor antagonist that reduces seizure activity in rodent models of epilepsy

  2011cited by this paper
• Erratum: Definition of drug resistant epilepsy. Consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies (Epilepsia (2010) 51 (1069-77))

  2010cited by this paper
• Neurocognitive effects of brivaracetam, levetiracetam, and lorazepam

  2010cited by this paper
• Quality of life and employment status are correlated with antiepileptic monotherapy versus polytherapy and not with use of "newer" versus "classic" drugs: results of the "Compliant 2006" survey in 907 patients.

  2010cited by this paper
• Brivaracetam (ucb 34714) inhibits Na(+) current in rat cortical neurons in culture.

  2010cited by this paper
• Revised terminology and concepts for organization of seizures and epilepsies: Report of the ILAE Commission on Classification and Terminology, 2005–2009

  2010cited by this paper
• Adjunctive brivaracetam for refractory partial-onset seizures

  2010cited by this paper
• Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies

  2009cited by this paper
• What is the promise of new antiepileptic drugs in status epilepticus? Focus on brivaracetam, carisbamate, lacosamide, NS‐1209, and topiramate

  2009cited by this paper
• SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy.

  2008cited by this paper
• Pharmacokinetics and Metabolism of 14C-Brivaracetam, a Novel SV2A Ligand, in Healthy Subjects

  2008cited by this paper
• Effect of brivaracetam on cardiac repolarisation – a thorough QT study*

  2008cited by this paper
• Brivaracetam and seletracetam, two new SV2A ligands, improve paroxysmal dystonia in the dt sz mutant hamster.

  2008cited by this paper
• Brivaracetam: a rational drug discovery success story

  2008cited by this paper
• Brivaracetam: a new drug in development for epilepsy and neuropathic pain

  2008cited by this paper
• Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures

  2008cited by this paper
• Anti‐convulsive and anti‐epileptic properties of brivaracetam (ucb 34714), a high‐affinity ligand for the synaptic vesicle protein, SV2A

  2008cited by this paper
• Results of treatment changes in patients with apparently drug‐resistant chronic epilepsy

  2007cited by this paper
• Brivaracetam is superior to levetiracetam in a rat model of post-hypoxic myoclonus

  2007cited by this paper
• Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model

  2007cited by this paper

• Bewährtes und Neues in der medikamentösen Epilepsietherapie

  2023cites this paper
• Replacement of Valproic Acid with New Anti-Seizure Medications in Idiopathic Generalized Epilepsy

  2022cites this paper
• Perampanel in achieving status epilepticus cessation: A systematic review.

  2022cites this paper
• Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Future Strategies

  2021cites this paper
• Efficacy, Retention and Tolerability of Everolimus in Patients with Tuberous Sclerosis Complex: A Survey-Based Study on Patients’ Perspectives

  2021cites this paper
• Perampanel effects on cognition and quantitative EEG in patients with epilepsy.

  2021cites this paper
• Efficacy and tolerability of intravenous brivaracetam for status epilepticus: A systematic review.

  2020cites this paper
• Cenobamate for the treatment of focal epilepsies

  2020cites this paper
• Therapeutic Options for Patients with Refractory Status Epilepticus in Palliative Settings or with a Limitation of Life-Sustaining Therapies: A Systematic Review

  2020cites this paper
• Comparison of the effectiveness and tolerability of perampanel and brivaracetam: a real-world, observational, retrospective study.

  2020cites this paper
• Clinical experience with brivaracetam in a series of 46 children.

  2020cites this paper
• Brivaracetam efficacy and tolerability in clinical practice: A UK-based retrospective multicenter service evaluation.

  2020cites this paper
• Medikamentöse Therapie von epileptischen Anfällen und Epilepsien

  2019cites this paper
• Novel drugs and early polypharmacotherapy in status epilepticus.

  2019cites this paper
• Intravenous brivaracetam in status epilepticus: Correlation between loading dose, plasma levels and clinical response.

  2019cites this paper
• Editorial: Burden of Illness in People With Epilepsy: From Population-Based Studies to Precision Medicine

  2019cites this paper
• Preliminary evidence about irritability in patients with epilepsy treated by perampanel as first add‐on therapy compared to levetiracetam and valproic acid

  2019cites this paper
• Effect of brivaracetam on the anger levels of epilepsy patients. A prospective open-labelled controlled study.

  2019cites this paper
• Recent advances in the pharmacotherapy of epilepsy: brivaracetam and perampanel as broad-spectrum antiseizure drugs for the treatment of epilepsies and status epilepticus

  2019cites this paper
• Intravenous Brivaracetam in the Treatment of Status Epilepticus: A Systematic Review

  2019cites this paper
• Brivaracetam in the treatment of epilepsy: a review of clinical trial data

  2019cites this paper
• First clinical postmarketing experiences in the treatment of epilepsies with brivaracetam: a retrospective observational multicentre study

  2019cites this paper
• Efficacy, retention, and safety of brivaracetam in adult patients with genetic generalized epilepsy.

  2019cites this paper
• Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus

  2018cites this paper
• Efficacy, Retention, and Tolerability of Brivaracetam in Patients With Epileptic Encephalopathies: A Multicenter Cohort Study From Germany

  2018cites this paper
• Topiramat, Perampanel und Brivaracetam im Status epilepticus

  2018cites this paper
• Postmarketing experience with brivaracetam in the treatment of focal epilepsy in children and adolescents.

  2018cites this paper
• Sulphuric body odor under therapy with Brivaracetam.

  2018cites this paper
• Efficacy and tolerability of perampanel and levetiracetam as first add-on therapy in patients with epilepsy: A retrospective single center study.

  2018cites this paper
• Eslicarbazepine acetate in epilepsies with focal and secondary generalised seizures: systematic review of current evidence

  2018cites this paper
• Brivaracetam in the Treatment of Patients with Epilepsy—First Clinical Experiences

  2018cites this paper
• Perampanel: Does it have broad‐spectrum potential?

  2018cites this paper
• Health care resource utilization before and after perampanel initiation among patients with epilepsy in the United States

  2017cites this paper
• Evaluation of brivaracetam: a new drug to treat epilepsy

  2017cites this paper
• Therapeutic Advances in Neurological Disorders

  2017cites this paper
• Perampanel in 12 patients with Unverricht‐Lundborg disease

  2017cites this paper
• Concepts for Prehospital and Initial In-hospital Therapy of Status Epilepticus

  2017cites this paper
• Konzepte zur prähospitalen und initialen intrahospitalen Therapie des Status epilepticus

  2017cites this paper
• Systemic Chemoconvulsants Producing Acute Seizures in Adult Rodents

  2017cites this paper
• The Pharmacology and Toxicology of Third-Generation Anticonvulsant Drugs

  2017cites this paper
• Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany

  2017cites this paper
• Antiepileptic Drugs and Liver Disease.

  2017cites this paper
• Eslicarbazepine acetate as a therapeutic option in a patient with carbamazepine-induced rash and HLA-A*31:01.

  2017cites this paper
• Treatment of refractory and super-refractory status epilepticus with brivaracetam: A cohort study from two German university hospitals.

  2017cites this paper
• Potent Anti-seizure Effects of Locked Nucleic Acid Antagomirs Targeting miR-134 in Multiple Mouse and Rat Models of Epilepsy

  2016cites this paper
• Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus

  2016cites this paper
• Auswirkungen der frühen Nutzenbewertung auf Patienten mit Epilepsie in Deutschland

  2016cites this paper
• Brivaracetam zur Zusatztherapie bei fokalen Epilepsien

  2016cites this paper
• Transition from intravenous to enteral ketamine for treatment of nonconvulsive status epilepticus

  2016cites this paper
• Perampanel for the treatment of primary generalized tonic-clonic seizures in idiopathic generalized epilepsy

  2016cites this paper